JPPT Clinical Investigation Proton Pump Inhibitor Prescribing Patterns in Newborns and Infants Marta Illueca, MD, Berhanu Alemayehu, DrPH, Nze Shoetan, MS, MBA, and Huiying Yang, MD, PhD AstraZeneca LP, Wilmington, Delaware OBJECTIVES: In 2011, the Food and Drug Administration (FDA) approved intravenous esomeprazole 0.5 mg/day for children aged >1 month and oral esomeprazole for infants aged 1 month to
